Annual Accounts Receivable
$47.10 M
+$12.95 M+37.90%
December 31, 2024
Summary
- As of March 13, 2025, VNDA annual accounts receivable is $47.10 million, with the most recent change of +$12.95 million (+37.90%) on December 31, 2024.
- During the last 3 years, VNDA annual accounts receivable has risen by +$14.63 million (+45.07%).
- VNDA annual accounts receivable is now -86.61% below its all-time high of $351.76 million, reached on December 1, 2003.
Performance
VNDA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$47.10 M
+$4.35 M+10.17%
December 31, 2024
Summary
- As of March 13, 2025, VNDA quarterly accounts receivable is $47.10 million, with the most recent change of +$4.35 million (+10.17%) on December 31, 2024.
- Over the past year, VNDA quarterly accounts receivable has increased by +$10.39 million (+28.30%).
- VNDA quarterly accounts receivable is now at all-time high.
Performance
VNDA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
VNDA Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.9% | +28.3% |
| 3 y3 years | +45.1% | +28.3% |
| 5 y5 years | +78.6% | +28.3% |
VNDA Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +45.1% | at high | +92.2% |
| 5 y | 5-year | at high | +78.6% | at high | +92.2% |
| alltime | all time | -86.6% | -100.0% | at high | -100.0% |
Vanda Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $47.10 M(+37.9%) | $47.10 M(+10.2%) |
| Sep 2024 | - | $42.75 M(+2.1%) |
| Jun 2024 | - | $41.86 M(+14.0%) |
| Mar 2024 | - | $36.71 M(+7.5%) |
| Dec 2023 | $34.16 M(+1.9%) | $34.16 M(+16.7%) |
| Sep 2023 | - | $29.27 M(-12.9%) |
| Jun 2023 | - | $33.62 M(+37.2%) |
| Mar 2023 | - | $24.51 M(-26.9%) |
| Dec 2022 | $33.51 M(+3.2%) | $33.51 M(+14.2%) |
| Sep 2022 | - | $29.35 M(+1.9%) |
| Jun 2022 | - | $28.80 M(-5.5%) |
| Mar 2022 | - | $30.50 M(-6.1%) |
| Dec 2021 | $32.47 M(+8.1%) | $32.47 M(-21.8%) |
| Sep 2021 | - | $41.50 M(+11.9%) |
| Jun 2021 | - | $37.09 M(+17.8%) |
| Mar 2021 | - | $31.47 M(+4.8%) |
| Dec 2020 | $30.04 M(+13.9%) | $30.04 M(+7.1%) |
| Sep 2020 | - | $28.03 M(+14.0%) |
| Jun 2020 | - | $24.59 M(-16.0%) |
| Mar 2020 | - | $29.27 M(+11.0%) |
| Dec 2019 | $26.37 M(-8.4%) | $26.37 M(-1.7%) |
| Sep 2019 | - | $26.82 M(+12.3%) |
| Jun 2019 | - | $23.89 M(-9.3%) |
| Mar 2019 | - | $26.35 M(-8.5%) |
| Dec 2018 | $28.78 M(+63.5%) | $28.78 M(+13.9%) |
| Sep 2018 | - | $25.26 M(+1.6%) |
| Jun 2018 | - | $24.86 M(+6.6%) |
| Mar 2018 | - | $23.31 M(+32.5%) |
| Dec 2017 | $17.60 M(-13.2%) | $17.60 M(-3.2%) |
| Sep 2017 | - | $18.18 M(-13.5%) |
| Jun 2017 | - | $21.02 M(+18.4%) |
| Mar 2017 | - | $17.75 M(-12.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $20.27 M(+24.1%) | $20.27 M(+27.2%) |
| Sep 2016 | - | $15.93 M(+13.5%) |
| Jun 2016 | - | $14.03 M(-15.9%) |
| Mar 2016 | - | $16.68 M(+2.1%) |
| Dec 2015 | $16.33 M(+346.9%) | $16.33 M(+3.4%) |
| Sep 2015 | - | $15.79 M(-0.2%) |
| Jun 2015 | - | $15.82 M(-21.4%) |
| Mar 2015 | - | $20.12 M(+450.6%) |
| Dec 2014 | $3.65 M(+79.9%) | $3.65 M(-1.1%) |
| Sep 2014 | - | $3.70 M(+55.6%) |
| Jun 2014 | - | $2.38 M(+40.5%) |
| Mar 2014 | - | $1.69 M(-16.7%) |
| Dec 2013 | $2.03 M(+73.9%) | $2.03 M(+3.8%) |
| Sep 2013 | - | $1.96 M(+19.2%) |
| Jun 2013 | - | $1.64 M(+12.2%) |
| Mar 2013 | - | $1.46 M(+25.2%) |
| Dec 2012 | $1.17 M(-27.8%) | $1.17 M(-23.9%) |
| Sep 2012 | - | $1.53 M(-9.7%) |
| Jun 2012 | - | $1.70 M(+10.7%) |
| Mar 2012 | - | $1.53 M(-5.1%) |
| Dec 2011 | $1.62 M(+216.6%) | $1.62 M(+33.1%) |
| Sep 2011 | - | $1.22 M(+61.7%) |
| Jun 2011 | - | $752.00 K(-16.0%) |
| Mar 2011 | - | $895.00 K(+75.1%) |
| Dec 2010 | $511.00 K(-83.8%) | $511.00 K(+3.4%) |
| Sep 2010 | - | $494.00 K(-24.6%) |
| Jun 2010 | - | $654.90 K(-89.3%) |
| Mar 2010 | - | $6.10 M(+92.7%) |
| Dec 2009 | $3.16 M(>+9900.0%) | $3.16 M(>+9900.0%) |
| Dec 2008 | $0.00(-100.0%) | $0.00 |
| Dec 2003 | $351.76 M(+14.9%) | - |
| Dec 2002 | $306.20 M | - |
FAQ
- What is Vanda Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual accounts receivable year-on-year change?
- What is Vanda Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Vanda Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of VNDA is $47.10 M
What is the all time high annual accounts receivable for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual accounts receivable is $351.76 M
What is Vanda Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, VNDA annual accounts receivable has changed by +$12.95 M (+37.90%)
What is Vanda Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of VNDA is $47.10 M
What is the all time high quarterly accounts receivable for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly accounts receivable is $47.10 M
What is Vanda Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, VNDA quarterly accounts receivable has changed by +$10.39 M (+28.30%)